Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

901 Walnut Street
4th Floor
Philadelphia, PA 19107

(215) 955 -7865
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. Advances in the diagnosis, immunopathogenesis and therapies of igm-anti-mag antibody-mediated neuropathies
  2. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy
  3. Gene therapy for Duchenne muscular dystrophy: Balancing good science, marginal efficacy, high emotions and excessive cost
  4. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  5. Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors
  6. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome
  7. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
  8. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis
  9. Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations
  10. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business
  11. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  12. Close to the node but far enough
  13. Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?
  14. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
  15. The spectrum of inflammatory myopathies: Dermatomyositis, polymyositis, necrotizing myositis, and inclusion-body myositis
  16. Necrotising autoimmune myopathy (NAM): Antibodies seem to be specific markers in aiding diagnosis
  17. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
  18. Efficacy of Intravenous Immunoglobulin in Neurological Diseases
  19. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
  20. Progressive encephalomyelitis with rigidity and myoclonus (PERM): Brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab